drugset
Drugs / Opevesostat
last change Jul 2026 re-read 2 minutes ago

Opevesostat

also known as MK-5684 · ODM-208

Small molecule

Developed for
castration-resistant prostate carcinoma · metastatic prostate carcinoma · cancer · metastatic neoplasm · prostate cancer
Investigated by
Merck Sharp & Dohme LLC · Orion Corporation, Orion Pharma · Daiichi Sankyo

Trials 14 · a red edge is where a trial was stopped

today NCT07548606 · Ph 1 NCT06979596 · Ph 2 NCT06863272 · Ph 1/2 NCT06860243 · Ph 1 NCT06814132 · Ph 1 NCT06633419 · Ph 1 NCT06566989 · Ph 1 NCT06554639 · Ph 1 NCT06353386 · Ph 1/2 NCT06136598 · Ph 1 NCT06136624 · Ph 3 NCT06136650 · Ph 3 NCT06104449 · Ph 1 NCT03436485 · Ph 1/2
20182019202020212022202320242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT07548606 May → Jun 2026 — Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06860243 May 2025 → Feb 2026 — Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06814132 Apr → Oct 2025 chronic renal failure syndrome, end stage renal failure Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06633419 Dec 2024 → Feb 2025 — Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06566989 Sep → Oct 2024 metastatic prostate carcinoma Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06554639 Jul → Aug 2024 prostate neoplasm Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06136598 Jan 2024 → Mar 2026 castration-resistant prostate carcinoma Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06104449 Nov 2023 → Feb 2026 castration-resistant prostate carcinoma Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT06863272 Jul 2025 → Apr 2031 expected castration-resistant prostate carcinoma, metastatic neoplasm Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 1/2 NCT06353386 May 2024 → Jan 2029 expected castration-resistant prostate carcinoma Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 1/2 NCT03436485 Mar 2018 → Jul 2026 overdue prostate cancer Orion Corporation, Orion Pharma Active not recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06979596 Aug 2025 → Nov 2027 expected cancer Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT06136624 Dec 2023 → Aug 2028 expected metastatic prostate carcinoma Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 3 NCT06136650 Dec 2023 → May 2028 expected castration-resistant prostate carcinoma Merck Sharp & Dohme LLC Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

FieldValueCited text
Known as Opevesostat ClinicalTrials.gov intervention name — accepted as the source's own label NCT06104449 ↗
9

NCT06633419 ↗

NCT06353386 ↗

NCT06136624 ↗

NCT06566989 ↗

NCT06979596 ↗

NCT06136598 ↗

NCT06136650 ↗

NCT06860243 ↗

NCT07548606 ↗
Known as MK-5684 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06554639 ↗
2

NCT06814132 ↗

NCT06863272 ↗
Known as ODM-208 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03436485 ↗
Action Inhibit “ODM-208, a novel inhibitor of cytochrome P450 11A1” PMID 38320513 ↗ Dec 2023
Modality Small molecule — CHEMBL5314533 ↗
Route Oral “co-administered with glucocorticoid and fludrocortisone, orally daily” NCT03436485 ↗